1) tors in modulating central aspects of the disease. |
2) avirus (SARS-CoV-2) which causes COVID-19 disease. |
3) virus (SARS-CoV-2), which causes COVID-19 disease. |
4) arrier integrity can be promoted to limit disease. |
5) ed with increasing age and cardiovascular disease. |
6) uch as rheumatoid arthritis and Crohn’s disease. |
7) lationship between NOU and cardiovascular disease. |
8) omes for most aspects associated with the disease. |
9) no confirmed treatment or vaccine for the disease. |
10) utic strategies to treat this devastating disease. |
11) the review goal was broadened to chronic disease. |
12) rs for atherosclerosis and cardiovascular disease. |
13) herbicide paraquat (PQ) with Parkinson's disease. |
14) mammalian and human early embryo loss and disease. |
15) uate the multi-system involvement of this disease. |
16) reatment of patients with severe COVID-19 disease. |
17) rain areas, at different ages, and during disease. |
18) isk of mortality in patients with chronic disease. |
19) type 2 diabetes mellitus and Alzheimer's disease. |
20) t fit all" in the treatment of autoimmune disease. |
21) the mechanism of APOL1 associated kidney disease. |
22) stinal organ development, physiology, and disease. |
23) ndrial import machinery involved in heart disease. |
24) cation, and current treatments of the PAH disease. |
25) effects on all molecular subtypes of the disease. |
26) e globin genes, collectively known as HbM disease. |
27) arious diseases, including cardiovascular disease. |
28) induces cytokine secretion during retinal disease. |
29) tamin D may affect the development of the disease. |
30) iduals, ~50% present with severe allergic disease. |
31) ion in males even after recovery from the disease. |
32) as regulatory cells during chronic liver disease. |
33) ment and progression of neurodegenerative disease. |
|